Retinoblastoma is the most common pediatric intraocular neoplasm. While retinoblastoma development requires the inactivation of both alleles of the RB tumor-suppressor gene (RB1) in the developing retina, additional genomic changes are involved in tumor progression, which progressively lead to resistance of tumor cells to death. Therapeutics acting at very downstream levels of death signaling pathways should therefore be interesting in killing retinoblastoma cells. The BH3 only proteins promote apoptosis by modulating the interaction between the pro-and anti-apoptotic members of the BCL-2 protein family, and this effect can be recapitulated by the BH3 domains. This report analyzes the effect of various BH3 peptides, corresponding to different BH3 only proteins, on two retinoblastoma cell lines, Y79 and WERI-Rb, as well as on the photoreceptor cell line 661W. The BH3 peptide BIRO-1, derived from the Bim death domain, was very effective in promoting Y79 and WERI Rb cell death without affecting the 661W photoreceptor cells. This cell death was efficient even in absence of Bax and was shown to be caspase-independent. While ROS production or AIF release was not detected from mitochondria of treated cells; BIRO-1 initiated mitochondria fragmentation in a short period of time following treatment.
Introduction
small anticancer drugs which target the anti-apoptotic members of the mitochondrial machinery offer a possibility to overcome the death resistance of cancer cells. Mitochondria is a key downstream element in the different programmed cell death pathways, i.e, apoptosis, autophagy and necrosis. Mitochondrial integrity is under the control of the proteins of the BCL-2 family (7). These proteins function as a life/death switch that integrates diverse inter-and intracellular events to determine whether the apoptotic pathway should be activated (8) . The switch operates through the interactions between pro-and anti-apoptotic members of the family. The pro-survival family members (BCL-2, BCL-X L , BCL-W, MCL-1, A1) are critical for cell survival, since loss of any of them causes cell death in certain cell types (9) . Consistently, BCL-2 overexpression induces drug resistance in various tumors cell types. The pro-apoptotic BCL-2 family members are divided into two classes: the BAX-like proteins (BAX, BAK and BOK) and the BH3-only proteins (BIM, BID, PUMA, NOXA, BMF, BAD, HRK and BIK) (10) (11) . Structural studies have revealed that the 20 amino acids BH3 domain of the BH3-only proteins is able to interact with specific residues of the BH1, BH2 and BH4 domains of the pro-survival members (9) , leading to their neutralization. Relating to BAX and BAK, they have been shown to be essential to the proapoptotic function of BH3-only proteins (12) . The lack of both Bax and Bak induces perinatal lethality in mice, while cells knockdown for both these proteins are resistant to overexpression of BH3-only proteins as well as to various stimuli known to activate the intrinsic apoptotic pathway.
Manipulating the balance between the pro-and anti-apoptotic BCL-2 family members presents a great opportunity to restore apoptosis in cancer cells (13) (14) (15) (16) (17) (18) (19) (20) (21) .
BH3-peptide-based approach utilizes the prodeath BH3 minimal death domains to reestablish mitochondrial sensitivity in tumoral cells (13) (14) . Small peptides derived from BH3 domains can retain an ɲ-helical structure (14) and are able to recapitulate pro-apoptotic effects. In cell-free assays consisting of isolated mitochondria, BH3 peptides disrupt complexes formed between pro-apoptotic and anti-apoptotic BCL-2 family proteins (22) , induce oligomerization of BAX and BAK followed by mitochondrial membrane permeabilization, and release of cytochrome c. These effects could be abolished by using BAK -/-mitochondria or by BCL-2 overexpression (22) . BH3 peptides delivered into tumor cells have been shown to engage apoptosis through BAX activation and cytochrome c release (18, 23) . Therefore, BH3 peptides can provide molecular targeting of anti-apoptotic members of BCL-2 protein family and potentially improve traditional therapy of cancer.
In this report, we studied the death potential of different BH3 derived peptides on two human retinoblastoma cell lines, Y79 and WERI-Rb, as well as on primary mouse retinoblastoma. A massive cell death was promoted by the BH3 peptide from BIM, through a mechanism that is caspase-independent, and that has necrotic characteristic.
Material and Methods

Chemicals
The different BH3 peptides were synthetized by NeoMPS (Strasbourg, France) and Auspep 
WERI-Rb, Y79 and 661W Cell Cultures
All the cell lines were cultured in RPMI 1640 medium supplemented with 100 μg/ml streptomycin, 100 units/ml penicillin, 1 mM sodium pyruvate, 2 mM glutamine and 10% fetal calf serum (20% for Y79). 661W cells were generously provided by Dr. M. Al-Ubaidi (University of Oklahoma, Olkahoma City, USA).
Isolation of primary tumoral cells
The SV40-LT transgenic mice developing retinoblastoma are a gift of JM O'Brien (Salk Institute for Biological Studies, La Jolla, California) (24) . The eye of sick mice was removed and tumor material was isolated. Primary tumor cells were immediately transferred into RPMI-1640 without FBS, minced, and washed with PBS to remove any residual blood. The washed cells were then cultured in RPMI-1640 containing 10% fetal bovine serum as above.
Cell Viability Assays
For viability assays, cells were seeded at a density of 10,000 cells per well in 96-well plates, incubated overnight in 10% FBS/RPMI (20% for Y79), then treated for varying lengths of time with increasing doses of ABT-737. Following treatment, ATP content was measured using the ATPlite assay, a luminescence ATP detection assay system developed by PerkinElmer using a microplate reader (Bio-Tek Instruments).
Hoechst/PI Staining
Dying cells were discriminated from normal cells by the Hoechst/propidium iodide (PI)
technique. Briefly, tumors were incubated with Hoechst 33342 (12.5 μg/mL) and PI (5 μg/mL) for 5 min before visualization under a fluorescence microscope.
FACS Analysis
Cell viability was evaluated by the annexin V/propidium iodide (BD Biosciences) double staining assay following the manufacturer's instructions. Y79 cells were centrifuged at the end of treatment, rinsed twice with PBS, and stained with Annexin V-FITC apoptosis detection kit I (BD Biosciences). Analysis was performed on the FACS Calibur using CellQuest software.
Caspases-7-and -3 activation
Cells were seeded at a density of 10,000 cells per well in 96-well plates, incubated overnight in 10% FBS/RPMI (20% for Y79), then treated for varying lengths of time with increasing doses ABT-737 (1, 3 and 10 ʅM) ), in presence or absence of cisplatine and etoposide.
Following treatment, caspase-3 and -7 activity was measured using the the Caspase-Glo® 3/7 assay from Promega.
The cleavage of PARP, a downstream substrate of caspase-3, was studied by western blotting experiment using an antibody that recognize the full length protein (105 kDa), as well as the cleaved form (85 kDa form).
Measurement of ROS level
Following exposure to ABT-737, cells were stained with either 10 ʅM of the dye dihydroethidium (HE, Invitrogen) to measure intracellular superoxide or 10 ʅM of the dye dihydrodichlorofluorescein-diacetate (H2DCFDA, Invitrogen) in 1 ml media to measure intracellular hydrogen peroxide. Cells were stained for 30 min at 37° C and fluorescence was measured using an EnVision 2103 Multilabel Reader (PerkinElmer).
Whole cell lysates
Cells were washed once in cold Phosphate Buffered Saline (PBS) and recovered by centrifugation. Briefly, cell pellets were dislodged into cold lysis buffer (20mM Tris-acetate pH 7.0, 0.27M sucrose, 1mM EDTA, 1mM EGTA, 50mM sodium fluoride, 1%Triton X-100, 10mM ɴ-glycero-phosphate, 1mM DTT, 10mM p-nitrophenyl-phosphate, and antiproteases), and centrifuged at 15,000 rpm for 20 minutes. Supernatants were recovered and stored at -70°C until use. Total protein in cell lysates was quatified by Bradford method.
Cell lysates used for immunoprecipitation were prepared in 0.1% Triton X-100 lysis buffer (standard lysis buffer with only 0.1% Triton X-100 ) .
Isolation of Mitochondrial Extracts
Cells were lysed by mechanical homogenization using a small pestle, and mitochondrial extraction was performed using the mitochondrial extraction kit from Pierce according to the manufacturer's instructions.
Western blotting experiments
Equal quantities of total protein lysates were resolved by 8-15% SDS-polyacrylamide gel electrophoresis and electrotransferred onto polyvinylidene difluoride membranes.
Nonspecific protein binding was blocked by incubating the membrane with a blocking solution (1x TBS, 0.1% Tween 20, 5% nonfat dried milk powder) for 1 h at room temperature. The blots were then probed with primary antibodies overnight. The immune complex was detected by using a peroxidase-conjugated secondary antibody and the chemioluminescent detection kit according to the manufacturer's specifications (Millipore).
For non-denaturing PAGE-SDS, b-mercaptoethanol was not added to samples.
Pull-down and Immunoprecipitation experiments
Y79 protein extracts (1 mg) were first incubated with a GST protein bound to glutathioneagarose beads for 3 h at 4° C. Following this pre-clearing step, the supernatant was incubated with a GST-BIRO1 fusion protein bound to glutathione-agarose beads for 16 h at 4° C. After four washes, the proteins pulled down with the GST-BIRO1 were subjected to SDS-PAGE and immunoblotting.
Immunoprecipitations were performed with the PIERCE Co-IP Kit as mentioned by the manufacturer.
Immunofluorescence Microscopy
Cells were grown on coverslips at 60% density and fixed in ice-cold acetone: methanol (1:1)
for 5 min at room temperature, followed by permeabilization with 0.2% Triton X-100/PBS for 5 min. Cells were then blocked using 2% bovine serum albumin in PBS for 1 h and incubated with the monoclonal anti-ezrin antibody at the dilution of 1:100. cell lines derived from primary retinoblastoma, in 661W photoreceptor cell line and in non ocular tumoral cells. While BAX was highly expressed in WERI-Rb, Rb4820, Rb6226, and in four different primary retinoblastoma tumors and in 661W cells, it was completely absent in Y79 cells (Fig 1.A) . BAK was lacking in Rb4820 and 661W. BCL-X L was abundantly expressed in Y79 and WERI-Rb, while MCL-1 was detected in both these human cells. These data suggest that WERI-Rb, the four PR and Rb6226 should be more sensitive to cell death induction than Y79 and Rb4820.
Induction of cell death in retinoblastoma cell lines using BH3 peptidic compounds Cellular delivery of peptides derived from the BH3 domain was achieved by linking BH3 sequences to the peptidic transporter TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] from HIV (10 amino acids, GRKKRRQRRR), known to have a good efficacy in crossing cell-membranes from different cell-types (25) , and in transducing healthy cells from various compartments of the eye following injection into the vitreous body or subretinal space of adult mice (26) . Various peptides were designed based on the chemical and conformational properties of BH3 domains (Table 1) .
To enhance protease resistance and improve stability, peptides were synthesized in D-retro inverso conformation (25) (26) . To assess the capacity of D-TAT peptides to cross the cell membrane, cell lines were incubated with the D-TAT-FITC-labeled peptide. As observed in figure 1 .B, the fluorescent peptide was able to very rapidly enter (1 h We next examined whether cell-permeable BH3 peptides could induce cell death by exposing Y79 and WERI-Rb to peptides corresponding to the BH3 domains of BIM, BAD, BIK and BOK. BIRO1 exhibited a massive killing activity (80%) (Figure 2 .A), while BAD displayed a moderate cell death induction, and the other peptides showed little, if any, killing effect. As a control, cells were exposed to a mutated form of BIRO1, BIRO1 MT, in which the conserved leucine and aspartate residues were mutated to alanine. The mutation of these two critical amino acids has been shown to disrupt interaction with other members of the BCL-2 protein family (19, 22) . The pro-death effect of BIRO1 MT was decreased compared to BIRO1, with only 20% of cell death (Fig 2.A) . SN50 peptide was used as a negative control, as a peptide unrelated to Bcl-2 proteins family.
To assess the kinetics of ATP content decrease in Y79 and WERI-Rb, cells were exposed to cytoskeleton. As shown in figure 2D , the treatment of Y79 with BIRO1 quickly induced outgrowths followed by cell membrane breakdown.
In order to investigate whether BIRO1 killing effect was restricted to Y79 and WERI-Rb cell lines, we tested cell death induction in 661W cells, as well as in non ocular tumoral cells.
MDA-465 cells were the only one to display cell death (60%) after exposure to 10 ʅM BIRO1 (Fig 2.E) . At higher peptide concentration (20 ʅM), U2OS and HCT-116 showed 80% and 50% cell death. As a control for toxicity of high peptidic concentration (>10 ʅM), cells were exposed to 20 ʅM of the mutated form of BIRO1. No toxic effect was observed.
Effect of BIRO1 on primary mouse retinoblastoma As the killing activity of BIRO1 was highly variable from one cell line to another, the effect of the peptide on primary retinoblastoma tumors was difficult to predict. Primary mouse retinoblastoma were isolated from the SV40-LT transgenic mice (24) and their sensitivity to BIRO1 was tested. Retinoblastoma tumors were very sensitive to BIRO1, as observed by Hoechst/PI staining, while BIRO1 MT had a weak effect (Fig 2.F) . These results instigate us to further examine BIRO1 efficacy in vivo in mouse retinoblastoma models.
Cell death induced by BIRO1 is caspases independant
The rapid ATP content decrease and the early PI staining observed in Y79 and WERI-Rb treated with BIRO1 suggested that a mechanism other than apoptosis was implicated in the cell death program. To assess whether caspases were involved, the broad-spectrum caspase inhibitor Z-VAD-FMK was added to Y79 and WERI-Rb exposed to BIRO1. The BH3 peptide induced cell death in the presence of Z-VAD-FMK (Fig 3.A) . In addition, we were unable to Y79 and WERI-Rb exposed to BIRO1 (Fig. 3.B) , while treatment with etoposide or cisplatine triggered caspases activation. Caspases activation can also be visualized by the cleavage of caspases substrate proteins. As shown in figure 3.C, Y79 and WERI-Rb exposed to BIRO1 did not lead to PARP cleavage, while cisplatine did. In agreement with a non-apoptotic death program, we were unable to detect any Bax translocation (data not shown), cytochrome c or AIF release in both human retinoblastoma cell lines (data not shown). Checking for DNA fragmentation, we noticed chromatin cleavage in WERI-Rb exposed to BIRO1 as well as to cisplatine (data not shown), while no DNA fragmentation was detected in Y79. These results suggest that a small fraction of WERI-Rb cells entered into apoptosis, while the majority of the cells died through necrosis. Relating to Y79, the absence of Bax most likely repressed any apoptotic program through the mitochondria, leading to a necrotic death process.
Cell death induced by BIRO1 did not implicate autophagy or necroptosis
To determine whether the autophagy or the necroptotic machinery were modulated in Y79
and WERI-Rb exposed to BIRO1, cells were pretreated with 3-methyladenine (3-MA) and necrostatin (Nec-1), an inhibitor of autophagy and necroptosis respectively. Neither 3-MA, nor Nec-1 did protect Y79 and WERI-Rb against cell death induced by BIRO1 (Fig 3.A) . To further confirm an autophagy-independent killing pathway, the absence of conversion of LC3I to the lipidated form LC3II was assessed (27) (28) (Fig 3.D) . Our data suggested therefore that BIRO1-induced cell death in Y79 and WERI-Rb was not mediated by autophagy or necroptosis.
Cell death induced by BIRO1 did not induce calpains activation or reactive oxygen species (ROS) production 
Calpains are important players in programmed necrosis. These calcium-activated proteases initiate lysosomal disruption (29) followed by the release of cathepsins and the rearrangement of the actin cytoskeleton (30) . To clarify whether BIRO1 induced modulation of calpains activity and downstream release of lysosomal proteases, we tested whether calpains inhibitors (calpastatin, ALLN) as well as cathepsin B and L inhibitors (ALLN) decreased BIRO1 effect on cell viability. Both calpastatin and ALLN failed to affect cell death induced by BIRO1 (Fig 3.A) .
ROS is another effector in cell death signaling pathways including apoptosis and necrosis. To explore its potential role in BIRO1-induced cell death, Y79 and WERI-Rb were pre-treated with the antioxidant BHA before exposure to BIRO1. As shown in Fig. 4A , BHA did not attenuate retinoblastoma cell death. We also evaluated BIRO1 effect on intracellular ROS production, i.e. hydrogen peroxide and superoxide, using two different fluorescent probes (HE or H2DCFDA). Exposure of WERI-Rb to BIRO1 did not result in an increase in intracellular ROS production, neither hydrogen peroxide (Fig 4.B) nor superoxide (data not shown), as measured by fluorescence emission. At the same time the BH3 mimetics ABT-737, known to induce WERI-Rb apoptosis (21) induced hydrogen peroxide production (Fig 4.B) . (32) . To assess whether any morphological changes in mitochondria was generated in Y79 following exposure to BIRO1, cells were stained with the fluorescent dye Mitotracker Red CM-H 2 Xros, and mitochondrial morphology was examined (Fig 5.A) . Untreated cells exhibited elongated tubular mitochondria, while mitochondria of Y79 treated with BIRO1 displayed a conversion of tubular fused mitochondria into isolated small punctuated organelles after 1 h only (Fig 5.A) , indicative of mitochondrial fragmentation.
Mitochondrial fragmentation can result either from an increase in fission activity or an inhibition of fusion (33) (34) (35) (36) . To address whether BIRO1 induced fragmentation by recruiting the key fission protein DRP1, we investigated the expression and localization of DRP1 in Y79.
Under normal conditions, the main fraction of DRP1 was cytosolic (Fig 5.B) , with a weak portion localized at mitochondria. Following exposure to BIRO1, we were unable to detect any translocation of DRP1 to mitochondria or DRP1 dimerization (Fig 5.C) . Furthermore, the treatment of Y79 cells with the DRP1 inhibitor mdivi1, which attenuates Drp1 self-assembly, showed no protective effect following BIRO1 treatment (Fig 5.D) . These results suggested that mitochondrial fission induced by BIRO1 in Y79 was DRP1-independent, and might implicate unidentified regulators.
Another possible pathway leading to mitochondrial fragmentation is the proteolytic processing and inactivation of OPA1. BIRO1 had no effect on OPA1 (Fig 5.E BIRO1 interacted with BCL-X L BIRO1 derived from the BH3 domain of BH3-only proteins induced necrosis in Y79 and WERIRb which implicated mitochondria. To determine which mechanism was responsible for the high Y79 and WERI-Rb sensitivity to BIRO1, we investigated the potential interaction between BIRO1 and anti-apoptotic membres of the BCL-2 proteins family. We detected an interaction of BIRO1 with BCL-X L in Y79 by pull-down experiments, while BIRO1 was unable to bind BCL-2 and MCL-1 (Fig. 6B) . We also verified whether other factors playing a role in mitochondria dynamics were able to interact with BIRO1 (Fig. 6B) . None of these factors were found to bind to BIRO1 in Y79. The mutated form of BIRO1 was unable to interact with BCL-X L (data not shown).
Our hypothesis was therefore that BIRO1/BCL-X L interaction induced necrosis by releasing a deleterious factor from BCL-X L . BCL-X L is known to bind different factors and we focused on the interaction of BCL-X L with BID, PUMA, DRP1, HK2, VDAC and PGAM5 in Y79 (Fig 6.C) . BCL-X L was found to interact with BID, HK2 and VDAC. Following treatment of Y79 with BIRO1, the BCL-X L /BID interaction was decreased while the BCL-X L /HK2 and BCL-X L /VDAC interaction were increased (Fig 6.D) . A similar experiment was performed with BIRO1 MT and no effect was observed (data not shown). one of the last step of the apoptotic process suggests that a small part of the WERI-Rb cells are able to initiate apoptosis. We also examined the effect of BIRO1 on mitochondria. BIRO1 promoted mitochondria fragmentation very rapidly (1 h), suggesting an early mitochondrial function in BIRO1 induced cell death.
As BIRO1 did not kill retinoblastoma cells by apoptosis, we assessed the potential roles of necrosis and autophagy. While autophagy can participate to cell death, its activation may also establish a cellular protection against certain stress, in particular following deprivation of nutrients, and therefore against cell death (37) . The BCL-2 protein family are implicated in controlling autophagy, although autophagic mechanisms are quite different from apoptotic ones, and require disctint regulator proteins (38) (39) (40) , including Beclin-1. We therefore tested whether BIRO1 was able to modulate the interaction of Beclin-1 with BCL2 and/or BCL-X L to induce autophagy. BIRO1 had no effect on the autophagic process in Y79 and WERI-Rb as observed by LCIIB absence following peptide treatment.
In necrosis, studies have shown that mitochondria may constitute a regulatory element.
Necrosis has long been considered as a passive process devoid of controlled signaling events.
However, evidences for a regulated necrosis mechanism are accumulating especially from studies of death receptors leading to TNF-induced necrosis, called necroptosis. In addition to the features of necrosis in BIRO1-treated Y79 and WERI-Rb, i.e., absence of caspases activation and DNA fragmentation, other observations support the necrotic cell death pathway. ATP content in both Y79 and WERI-Rb dropped rapidly and cell membranes were quickly permeabilised. However, other events involved in necrotic cell death were not seen in BIRO1 induced cell death, such as calpain activation or ROS production. In necroptosis, the kinase RIP1 disrupts the interaction of the adenine nucleotide translocase (ANT) with cyclophilin D at the mitochondrial inner membrane, causing mitochondrial dysfunction and 
cell death (41) . We have examined whether RIP1 was involved in BIRO1 cell death using Nec-1, an allosteric inhibitor of RIP1 (42) able to protect cells from necroptosis. This inhibitor had no protective effect, suggesting therefore that BIRO1 induces a programmed necrosis different from necroptosis.
BIRO1-induced programmed necrosis directly implicated mitochondria. Indeed, the Y79 mitochondria, which displayed an elongated filamentous morphology under basal conditions, showed an altered fragmented shape and size following BIRO1 exposure.
Mitochondrial fission is a process associated with apoptosis, as well as with programmed necrosis or mitophagy. DRP1 has been shown to be involved in mitochondrial fission (33, 36) , its translocation from cytosol to mitochondria inducing mitochondria constriction. In Y79, we were unable to detect any DRP1 translocation to mitochondria, suggesting that unidentified regulators of fission machinery might contribute to cell death induced by BIRO1.
PGAM5 seems also to play an important role in mitochondrial dynamics at the interphase of apoptosis, necrosis and autophagy, as reported (43) . The PGAM5 gene encodes two protein isoforms, PGAM5-L (32 kDa) and PGAM5-S (28 kDa), both expressed at the level of the outer mitochondrial membrane (OMM). The accumulation of the PGAM5-S results in the formation of fragmented mitochondria (43) . PGAM5 has been shown to be activated in necroptosis triggering DRP1 dephosphorylation and translocation to mitochondria leading to mitochondria fragmentation (44) . In addition, upon mitochondrial membrane potential loss, PGAM5 is cleaved (45), being therefore a good marker for this event. We observed that BIRO1 induced an accumulation of the cleaved PGAM-L isoform. As PGAM5 has been shown to interact with BCL-X L (46), we verified whether BIRO1 acted in Y79 by modulating PGAM5/BCL-X L interaction. This was not the case (Fig 6.D) . We were then unable to 
determine whether BIRO1 had a direct effect on PGAM5 or whether PGAM5 cleavage was a secondary effect of BIRO1 on mitochondria. This point needs additional clarification.
VDAC is another abundant protein of the outer mitochondrial membrane playing a role in mitochondria-mediated cell death (47, 48) when it sets up channels in the OMM. The conductance throughout these channels is modulated by various factors including VDAC/BCL-X L interaction, which allows the channel to be in an open state, maintaining adenine nucleotide flux and the outer membrane permeability. The disruption of the VDAC/BCL-X L interaction triggers mitochondrial permeability modulation and cell death (49) (50) . In Y79, BIRO1 seemed to strengthen the VDAC/BCL-X L binding (Fig 6D) , which is in discrepancy with the protective effect of the VDAC/BCL-X L interaction.
Our study demonstrated that BH3 peptides enhanced cell death in retinoblastoma cells. Our finding is supported by a recent report (21) showing that retinoblastoma cells are sensitive to another BH3 mimetics, ABT-737. Further investigations are however necessary to clarify the exact mechanisms involved in the cell death process induced by BIRO1. From our study, it appears that an unknown programmed necrotic mechanism is implicated. A. Y79 and WERI-Rb were treated with 10 ʅM BIRO1 for 24 h. Prior to BIRO1 treatment, cells were exposed for 1 h to 100 ʅM BHA (antioxidant). Cell viability was determined by measuring ATP content of the cells using a luminescence assay. Independent experiments have been repeated three times. Dark grey column, Y79; grey column, WERI-Rb.
B. WERI-Rb cells were treated with 10 ʅM BIRO1 during 1 h and further stained for 30 min with H2DCFDA, a cell-permeable indicator for ROS. Changes in overall fluorescent intensity observed after exposure to BIRO1 was measured and quantified using an alpha-screen apparatus. As a positive control, cells were exposed to 1 ʅM ABT-737 and 100 mM H2O2, which caused a rapid 50% and 100% increase of ROS respectively. Independent experiments have been repeated three times. 
